Member Info for stu485

Mr I,

I have no need to ramp or de-ramp, just pointing out it’s a genuine article albeit a poor one.

Like you and others, I’m waiting for the next RNS to move the dial. I hope for all that it arrives soon !

AIMO

Mr I,

It is a standard template article the publisher uses mostly for small/mid cap Bio’s, with the specific company numbers entered, this time seemingly incorrectly.

It’s simply to generate interest, “click bate” i think the appropriate description.

Cash runway is a concern and is more of a concern since CH as VS himself highlighted within his interview.

“Clinical hold has changed our cash position”, from memory, roughly what he said.

All precisely why I’m expecting news to lift the SP to a level where a placing could help further extend the cash runway.

All informed investors will realize the necessity “IF” Hemo’ Car-T is to progress through to clinic.

AIMO

I'm not here to falsely excite and will call out BS if and when I see it.

Not watching this board too closely so no doubt the BS will flow when the pump comes.

Probably when Tilly re-appears from another convenient fantasy sail .

AIMO

Hulver,

…and so what !!!

You’re trying to imply it’s a big deal, it’s not !

AIMO

Wynn,

Yes you did and the reason I stayed out. At least you have the intellect to see it as it is now despite the angry mob.

I made a poor job of trying to explain what you have very eloquently , the tirade of abuse for daring to suggest the emperor is indeed in the buff, enough for me to leave well alone.

Hope your not overly exposed ( no pun intended)

Good luck.

AIMO

HT,

…or you could try and explain with insight/research why I’m wrong !?

Have a nice weekend.

HH,

As previous, In my opinion the next RNS will not be regarding Hemo' Car-T .

However on the H Car-T subject I think it's important to dispel the too convenient argument that the fix could have been made and re-submission already with the FDA.

...It's not and it's not !

With reference to your post.

1.It is not subjective ! They're literally the rules and should Hemo' apply their core value of "Integrity" to market comms, then they should and will RNS the re-submission. I think all would agree, if and when Hemo' are confident with their fix to the FDA highlighted deficiency and happy to present to the FDA, at THAT point, the SP would substantially move if same communicated to the market.

2.Hemo' have NOT told us they have solved the issue!

They have told us they have a method to solve the issue. It may appear like nit picking semantics, it's not, they are very, very different. Your assertion is incorrect.

I do agree with you that in general terms the most important factor is the FDA acceptance of a fix, if and when it's proposed.

However, strictly regarding the rules on RNS comms, the rules would dictate the need to RNS when Hemo' have determined they themselves have fixed the issue and re-submitted. It is not a subjective matter and as such it's not already done.

AIMO

Ps Genuinely glad you're back making lucid argument, even where we disagree. Before you say it, I know it's not mutual.

---------------------------------------------------------------

"This is subjective

“In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement.”

Hemo have already told us they have solved the single issue.

So whether you like it or not, I don't think submitting the paperwork is any more important that any other step required to address the 1 issue.

The significant thing is the FDA agreeing with Hemo that they have addressed the issue and lift the clinical hold

I have already "Priced In" the fact that Hemo will respond to FDA. So what matters to be is the response of the FDA"

HH,

Already have, please learn to properly read posts !

I stated, they may choose not to but run the risk of FCA scrutiny.

Given it’s Hemo’s lead product that’s presently considered a fail by the FDA, should Hemo’ be satisfied they had now fixed to the extent they’re confident with re-submitting that could make a material difference to the stock price, with market comms.

See below…again !

“In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement.”

Should you disagree then you must consider a new fix of Car-T would not make a “substantial share price movement “

Just please stop with the fantasy!

AIMO

…MrI, I’m afraid you’re wrong on that point .

The FDA advised failure is fundamental to the Car-T product. I’m sure (considering my own research), there’s a good deal of proving works to complete prior to re-submitting. Then there’s 30days FDA consideration and even then , there’s no guarantee of lifting CH. So yes , I’m not expecting anything

My view as valid as some who’d have you believe FDA have rubber stamp inked and hovering over revised documents.

Ask yourself, would Hemo’ want to keep it a secret if they’ve already fixed the issue ???

JFH’s(95%) argument that they wouldn’t want to offer a trading opportunity is very convenient for all investors to believe in a situation where there’s only bad news available!

AIMO

Mr I,

Well said. This is no place for inaccurate racial stereotypes pathetically disguised as humour, it’s not 1970 !

Regarding my posts, there’s nothing cryptic about them.

Simply correcting some of the garbage others spout and suggesting a straight forward position, in the hope others with insight and intelligence confirm or offer alternative researched opinion.

As previous, I think we’re in for a good rise soon but not expecting IND re-submission RNS before year end .

AIMO

…Good point and fingers crossed.

Hopefully the recent deterioration in general market sentiment won’t complicate any concluding negotiations that may well be at the point of dotting i’s and crossing t’s !

Good news soon I expect.

AIMO

HH,

You’re wrong!

To use your car analogy…it’s a different car altogether and it’s performance (suitability) will need to demonstrated all over again.

As for RNS on re-submission, they should as the rules determine. They risk FCA scrutiny should they choose not to.

Keep trying though, as sooner or later you’ll actually be correct.

AIMO

Mr I,

To be clear, i do not have any inside information.

I’m glad to see you’ve learnt to be sceptical.

Personally i think the company have recently been open and reasonable with shareholders. In my view it’s all down to very carefully considering what’s in RNS’s and what’s not!

As for the LSE bunch, some make valid and informed comment, many more will deliberately deceive !

AIMO

… i don’t know , hopefully before W2 Sept but that’s just a wishful guess.

AIMO

MrI,

I hope for both of us there’s a good rise coming.

Like you I’m expecting a rush for the door when it does and guess who could be leading the charge with their tranche 1 stock options !?

AIMO

Mr I,

CDX or other but not Cart-IND…yes that’s my belief.

I thought you were selling up ?

AIMO

MrI,

I’m already back in and will not be adding further.

To answer your questions.

1.Yes

2.Not sure that’s a question, i think just obvious agreement

3.Already showed you, bottom of my first message!

MJ, very good point !

AIMO

Pumpky,

VS has already explained the CH has changed their cash position. I don’t think he meant in a good way!

My expectation, an RNS on CDX or other distraction with associated (undeserved) rise and a subsequent placing before you can blink to cover the now anticipated cash burn to continue with Car-T.

I’m only here to trade on next RNS as have zero faith in longterm.

As previous, long way to go to re-submitting and they will have to RNS upon re-submitting, and not that ridiculous fairytale 95% suggests.

AIMO

The FDA highlighted issue is fundamental in the product suitability .

As such the PQ runs will be needed all over again to demonstrate the revised product quality & suitability.

As their lead product, the company will be required to RNS their re-application when it’s sent to comply with the rules below.

They may have started the new PQ process or they may not!

VS mentioned the company cash position has changed due to CH, so they might be waiting on a different catalyst before a further placing to raise funds to fully proceed with the full re-application works.

All above my opinion based on my own research.

It might all be as others suggest …(95% !)

DYOR !

“ issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement”

…Well , I believe it’s more a message for a potential buyer(s) than an update for shareholders.

That message, don’t expect to get TIC on the cheap and do expect to be in competition!

AIMO